














p53 continues to surprise biologists.  For nearly a 
decade, it was thought to be an oncogene [1, 2], only to 
be subsequently declared a potent tumor suppressor [3, 
4].  Initially characterized as a transcriptional activator, 
we now know p53 is also a transcriptional repressor [5].  
And just as it seemed p53 activities were confined to the 
nucleus, it became apparent that p53 also functioned in 
the cytoplasm to regulate mitochondrial responses [6, 
7].  As a tumor suppressor and regulator of hundreds of 
genes [5], it was perhaps not surprising that p53 was 
shown to regulate numerous cellular processes related 
to cancer -- cell cycle progression, apoptosis, cellular 
senescence and DNA repair, among others.  It was 
another surprise, however, to learn that p53 might also 
regulate aging.   
 
Half a dozen or so years ago, two landmark studies 
showed that, in mice, the constitutive expression of 
certain p53 mutants or naturally occurring isoforms 
resulted in chronically elevated p53 activity.  These 
transgenic mice were extraordinarily cancer resistant -- 
but they showed multiple signs of accelerated aging and 
died prematurely [8, 9].  This pro-aging activity of p53 
was thought to result from chronic p53-dependent 
apoptosis and/or senescence, resulting in cancer-
resistance at the price of tissue atrophy or dysfunction 
[10, 11].  Shortly thereafter, though, mice were 
engineered with extra copies of the wild-type p53 gene, 
and so they showed elevated p53 activity but in a 
normally regulated manner.  These mice were also 
extraordinarily resistant to cancer, but in this case they 
showed no signs of accelerated aging and had a normal 
life span [12].  Further, transgenic mice that 
overexpressed regulated p53 together with its upstream 
regulator ARF (p19) were not only cancer resistant but 
they lived significantly longer than wild-type controls 
[13].  In these models, the regulated hyperactive p53 
activity was shown to reduce age-associated DNA 
















Together, these studies indicate that p53 can promote or 
retard aging, depending on the context of its regulation 
and activity.   
 
One obvious mechanism by which p53 might exert both 
its pro-aging and pro-longevity effects is by driving cell 
fate decisions.  As a pro-aging determinant and as 
discussed above, p53 might drive excessive apoptosis 
and/or cellular senescence.  These cell fates can, in turn, 
cause tissue atrophy and degeneration (apoptosis) and 
loss of tissue renewal or regenerative capacity 
(senescence).  As a pro-longevity determinant, p53 
might eliminate damaged or dysfunctional cells 
(apoptosis) or prevent their proliferation and hence their 
ability to form tumors (senescence).   
 
A perhaps less obvious mechanism by which p53 might 
promote or retard aging is by altering the systemic or 
local tissue milieu.  One potentially important p53 
target in this regard is the insulin/insulin-like growth 
factor (IGF)-1 signaling (IIS) pathway.  IIS and one of 
its major intracellular targets, the mTOR pathway, drive 
aging in diverse species, ranging from yeast to mice 
[14].  In general, high IIS/mTOR activity is associated 
with cell proliferation, growth and aging, whereas low 
IIS/mTOR activity is associated with somatic 
maintenance and longevity.  In addition, p53 is 
regulated, directly and indirectly (through MDM2), by 
another major component of IIS signaling, the 
PKB/AKT kinase [15].  PKB/AKT signaling in turn is 
also both pro-aging (through the NF-kB transcription 
factor) and pro-longevity (through FOXO transcription 
factors) [16]. 
 
As is the case for all complex pathways, the precise 
phenotypes that are elicited by IIS/mTOR depend on the 
strengths of the activating or repressing signals, and on 
physiological context.  As a pro-aging determinant, p53 
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of IIS in mice with elevated p53 activity?   
Inconsistently, higher levels of circulating IGF-1 and 
tissue-associated IIS are present in both a short- [9] and 
long-lived [17] transgenic mouse with elevated p53 
activity.  Moreover, a second short-lived hyper-p53 
mouse model showed reduced IIS, at least in the 
mammary gland [18].  Further, IGFBP-3, a secreted 
IGF-1 binding protein that inhibits IGF-1 signaling, is a 
classic target of p53 transactivation activity [19].   
Clearly, whether and to what extent the effects of p53 
on aging and longevity are mediated by IIS must be 
determined in each of the mouse models, taking into 
account the multiple ways in which IIS activity can be 
modulated.   
 
A second potentially important p53 target is the 
senescence-associated secretory phenotype (SASP).  As 
discussed above, p53 is an important regulator of 
cellular senescence [20], the essentially irreversible 
arrest of cell proliferation that occurs in response to 
potentially oncogenic stresses [21].  We recently 
showed that senescent cells secrete a plethora of 
biologically active molecules that can alter the systemic 
or local tissue milieu [22, 23].  Of particular 
significance, p53 restrained the SASP [22].  That is, 
compared to wild-type cells, cells that lacked p53 
function secreted markedly higher levels of most of the 
SASP components.   
 
A striking feature of the SASP is the prevalence of pro-
inflammatory cytokines [24, 25].  Low level, chronic 
inflammation increases with age and is a cause or 
substantial contributor to virtually all of the major age-
related diseases [26-29].  The source of this 
inflammation is not clear, but one possibility is that it 
derives at least in part from senescent cells, which 
increase with age [30].  It is tempting to speculate, then, 
that p53 might have pro-longevity effects not only 
because it suppresses tumorigenesis, but also because it 
keeps in check inflammation driven by senescent cells.   
 
It is evident now that p53 can be either pro-aging or 
pro-longevity, depending on the physiological context.  
The apparent paradox of how p53 modulates life span 
will undoubtedly resolve as we understand in greater 
detail how p53 and its activities impact specific aging 
phenotypes.  And in this regard, p53 will likely continue 
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